Compare Advanced Micro Devices (AMD) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Ascendis Pharma A/S — how do they compare? Advanced Micro Devices trades at $534.33 (market cap $909.70B), while Ascendis Pharma A/S trades at $265.33 (market cap $17.74B). The key difference: Advanced Micro Devices is far larger — about 51.3× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| AMD | ASND | |
|---|---|---|
Market Cap | $909.70B | $17.74B |
Sector | Technology | Health |
52-Week High | $580.91 | $277.18 |
52-Week Low | $146.24 | $163.32 |
Enterprise Value | $901.22B | $18.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $34.64 billion and net income surging to $4.34 billion, though valuation ratios like P/E of 185.96 indicate premium pricing. Recent earnings beats and positive AI-driven news fuel investor optimism.
Outlook remains positive due to AI demand and earnings momentum, but high valuations and intense competition pose risks. Analyst consensus is strongly bullish with a $508.24 price target, though the stock trades above this, suggesting near-term caution amid long-term growth potential.
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
